摘要
目的:探讨西妥昔单抗联合奥沙利铂、卡培他滨治疗晚期结肠癌的临床疗效。方法:选取107例晚期结肠癌患者作为研究对象,根据治疗方式不同将患者分为对照组(n=52)和试验组(n=55)。对照组予以奥沙利铂联合卡培他滨化疗方案治疗;试验组在对照组基础上予以西妥昔单抗治疗,21 d为1个疗程,两组患者均治疗两个疗程。比较两组治疗前后karnofsky评分(KPS)、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原199(CA199)]和细胞免疫功能指标。记录并比较两组患者临床疗效和不良反应。结果:与对照组比较,试验组总有效率更高(63.64%vs.38.46%,P<0.05)。治疗后,试验组KPS评分高于对照组(P<0.05);血清CEA、CA199水平低于对照组(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)T细胞水平相比治疗前均降低(P<0.05),但试验组高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:西妥昔单抗联合奥沙利铂与卡培他滨治疗晚期结肠癌能够提高临床疗效,降低患者血清肿瘤标志物水平,改善免疫功能。
Objective:To investigate the clinical efficacy of cetuximab combined with oxaliplatin and capecitabine in the treatment of advanced colon cancer.Methods:A total of 107 patients with advanced colon cancer were divided into control group(n=52)and experimental group(n=55)according to different treatment methods.The control group was treated with oxaliplatin combined with capecitabine chemotherapy,and the experimental group was treated with cetuximab on the basis of the control group.21 d was a course of treatment,and both groups were treated for 2 courses.The karnofsky score(KPS),serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)]and cellular immune function indexes were compared before and after treatment.The clinical efficacy and adverse reactions of the two groups were observed.Results:Compared with the control group,the total effective rate of the experimental group was increased(63.64%vs.38.46%,P<0.05).After treatment,the KPS score of the experimental group was higher than that of the control group(P<0.05),and the serum CEA and CA199 levels were lower than those of the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before treatment(P<0.05),and the experimental group was higher than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Cetuximab combined with oxaliplatin and capecitabine in the treatment of advanced colon cancer can improve the clinical efficacy,reduce the level of serum tumor markers and improve the immune function of patients.
作者
庄佳芳
李扬
徐斌
李迪
陈战
欧阳山丹
ZHUANG Jia-fang;LI Yang;XU Bin;LI Di;CHEN Zhan;OUYANG Shan-dan(Department of Pharmacy,the 73rd Group Military Hospital of Chinese People s Liberation Army,Xiamen 361000,Fujian,China;Department of General Surgery,the 73rd Group Military Hospital of Chinese People s Liberation Army,Xiamen 361000,Fujian,China)
出处
《川北医学院学报》
CAS
2023年第10期1367-1370,共4页
Journal of North Sichuan Medical College
基金
福建省厦门市医疗卫生指导性项目(3502Z20209156)。
